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A View From Inside Industry:
A Response to Professor Walker's Challenges
ALLAN J. WEINSTEIN, M.D.*
INTRODUCTION
Successfully dealing with the four challenges described by Professor
Walker is critical to both the effective management and the financial stability
of the research-based pharmaceutical industry. The interplay of government,
industry, and the consumer is also a critical factor in determining whether
these challenges can be met. The very character of these three participants
(government, industry, and consumers) has changed dramatically in recent
years. Governments, while historically involved in the drug review and
approval process, have become progressively more active in providing health
care to their populations; in some countries this involves establishing standards
of care. Industry consolidation, as discussed by Professor Walker, has resulted
in fewer but larger providers of pharmaceuticals, whose increasingly large
research expenditures are being directed both at newly emerging diseases, such
as AIDS, and diseases for which current treatment is considered to be less than
satisfactory, such as depression and malignancy. Finally, the traditionally
recognized consumers for pharmaceutical products have been members of the
medical profession: physicians and surgeons. In recent years, there has been
a dramatic redefinition of "consumers" to include managed care organizations,
governments, buying groups, pharmacy benefit managers, and patients
themselves.
These changes in the nature of the principals involved in the
pharmaceutical interaction have been accompanied by three increasingly
important developments within the industry. The first of these developments
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is the requirement that, prior to approval, new pharmaceutical agents must be
shown not only to be effective and safe, but also must conclusively be
demonstrated to be cost-effective and/or to provide an improved quality of life.
This requirement is now mandated in Australia and Canada and is certain to
be required eventually in other countries.
The second development is the recognition that new drugs must provide
significant advances over their predecessors. In light of the redefinition of
potential consumers of pharmaceutical agents, small increments of change will
not be rewarded by the marketplace and, in simple terms, people will no longer
pay for "me-too" drugs. The final important development within the
pharmaceutical industry is the understanding that the targets of new drug
development, particularly malignancy and diseases of the central nervous
system, will require significantly greater expenditures and the application of
considerably more advanced technology than many, if not most, of the
infectious, cardiovascular, and gastrointestinal diseases which have yielded to
pharmaceutical innovation in the past. It is in the context of the changing
nature of the challenges faced by the global pharmaceutical industry and the
changing nature of its stakeholders that I will respond to Professor Walker's
analysis by reflecting on my experiences inside a global pharmaceutical
company.
I. REMAINING PROFITABLE
Professor Walker describes vertical and horizontal integration, mergers
and acquisitions, and increasing expenditures on research and development
(R&D) as means utilized by the pharmaceutical industry to maintain current
levels of profitability. While horizontal and vertical integration have
increased, these are not the only strategies available to address the profit
challenge. Eli Lilly and Company (Lilly) has chosen an alternative strategy
to profitability that is not related to company size or integration. The dominant
factor in Lilly's strategy to remain profitable is pharmaceutical innovation.
We define pharmaceutical innovation as the series of processes of value
creation that convey a biomedical discovery into a pharmaceutical product that
is desired-and, therefore, will be paid for-in the marketplace.
Lilly believes that, with R&D efforts directed toward the goal of profitable
pharmaceutical innovation, we can provide benefits to shareholders,
employees, and patients alike. The companies that will be financially
successful are those that can deliver truly innovative solutions to health care
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problems. This type of innovation cannot be automatically achieved simply
through horizontal integration, vertical integration, or increased R&D
expenditures. Professor Walker noted that the profit and innovation challenges
are interdependent, and Lilly's strategy reflects the critical importance of
pharmaceutical innovation to profitability.
II. CARRYING OUT INNOVATIVE DISCOVERY RESEARCH
Professor Walker has documented the major advances in therapy since
1980. He has mentioned, and I will strongly emphasize, two developments:
the disappearance of the "not invented here" syndrome and the advent of new
technologies. Historically, research in the pharmaceutical industry was rather
insular and, perhaps, arrogant. It was believed that industry was the prime
residence of expertise related to drug discovery and development, and that
there was little to learn from others. Fortunately, the past ten to fifteen years
have witnessed the virtual disappearance of this attitude. There are few, if any,
major research-based pharmaceutical companies that do not have a significant
number of research alliances with universities, institutes, and small
biotechnology concerns. While the majority of these alliances are with entities
in the United States, there are also rapidly growing collaborations with
organizations in Europe and the Asia-Pacific region. Just as the market for
pharmaceutical products has truly gone global, the search for innovative new
drugs is also taking shape as a global endeavor involving researchers and
companies at many different levels of an economy in many different countries.
What we are witnessing is the decentralization and globalization of
pharmaceutical R&D.
The advent of newer technologies has greatly enhanced the opportunities
for innovation. Within the past ten years, the field of genomics has arisen.
This field holds the promise of understanding the genetic basis of a wide range
of diseases and offers for the first time the possibility for innovative
pharmaceuticals to target the precise genetic defect in a disease agent.
Combinational chemistry and high throughput screening' now enable us to test
hundreds of thousands, even millions, of chemical compounds in the period of
I. Until recently, chemists working with traditional tools could assemble new molecules only one at
a time. However, by using combinatorial chemistry, those same chemists can now assemble thousands of
new molecules within days. They are now synthesizing compounds 100 times faster than in the past and
are screening them faster to find the most promising drug candidates.
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time in which only hundreds or thousands of compounds could have been
tested in the past. These technologies have already produced "drug
candidates", chemicals that have the potential to be developed into
pharmaceuticals, which may never have been identified or, if identified, would
have required significantly longer periods of time to identify. New
technologies might help reshape the nature of pharmaceutical development, as
new technologies have revolutionalized other economic sectors, such as
telecommunications. In addition, these new technologies will accelerate the
decentralization and globalization of pharmaceutical R&D already taking place
in the industry.
III. BRINGING NEW MEDICINES MORE QUICKLY TO THE MARKETPLACE
As noted by Professor Walker, it has historically required ten to twelve
years to develop a new pharmaceutical agent. Virtually all major research-
based pharmaceutical companies have recognized that such a development
time is unacceptable from the perspective of consumers, company
management, and shareholders. Most companies have embarked on major
"reengineering" efforts in an attempt to shorten this time.'
At Lilly, we have made a commitment to reduce our drug development
time from our historical duration of 4700 days (twelve to thirteen years) to
2500 days (seven years). At the present time, through reengineered activities
and without a substantial increase in resources, we have been able to move
from 4500 days to 3300 days. The application of new technologies, from
robotics to information technology, has been central to the advances made thus
far. Even greater advances will be possible in the future as science progresses.
For example, if the possibility of using non-animal systems to study safety
(toxicology) were to become a reality, the development time required to bring
a new drug to market would be reduced even more.
IV. ENSURING A RAPID AND EFFICIENT REVIEW PROCESS
As Professor Walker indicated, ensuring that the regulatory review process
is both rapid and efficient should be a responsibility shared by the
pharmaceutical industry, regulators, and consumers. The pharmaceutical
2. Development time is defined as the time from formation of a cross-functional team responsible for
development of a promising new chemical until launch into two-thirds of the world's market.
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industry must utilize all available technology in order to provide complete,
relevant, and scientifically valid information to regulators in an accessible and
understandable form. When regulating new drugs, regulators must require
only that data which is necessary to make reasoned decisions concerning the
efficacy, safety, cost-effectiveness, and/or quality of life attributes of the new
drugs. Consumers must exert appropriate pressure on both the pharmaceutical
industry and regulators to ensure that appropriate data is efficiently reviewed;
as a result, useful drugs will not be denied to patients for extended periods of
time.
Recently, two developments have provided hopeful indications concerning
the speed and efficiency of the drug review process. The formation of the
European Medicines Evaluation Agency provided a centralized procedure of
review by which it is possible for there to be virtually simultaneous approval
for marketing in all fifteen European Union member states? On a more global
basis, the International Conference of Harmonization (ICH), which has existed
for approximately four years, brings together regulators and pharmaceutical
manufacturing associations from the United States, Japan, and the European
Union. The goal of the ICH is to use input from industry to obtain as much
harmonization as possible among the drug approval requirements of the parties
involved. To date, a significant amount of progress has been made: guidelines
in the three geographical areas have been modified, and the process for even
more enhanced transparency among regulations across the jurisdictions
involved in the ICH process has been implemented.' Such international
harmonization has been, and will continue to be, an important factor in
streamlining the regulatory review process. The need for regulatory
harmonization at the intergovernmental level mirrors the need for more
creative and collaborative R&D approaches in the industry. Just as
pharmaceutical companies abandoned the "not invented here" syndrome,
national regulatory agencies learned to operate in a global system of
pharmaceutical regulation.
3. Evelyne Friedel & Michael Freundlich, European Community Harmonization of the Licensing and
Manufacturing of Medicinal Products, 49 FOOD & DRUG L.J. 141, 163 (1994).
4. Joseph Contrera, The Food and Drug Adminstration and the International Conference on
Harmonization: How Harmonious Will International Pharmaceutical Regulations Become?, 8 ADMIN. L.J.
AM. U. 927,939-55 (1995).
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CONCLUSION
The four challenges facing the pharmaceutical industry described by
Professor Walker are difficult and interdependent challenges. Whether the
strategy be horizontal integration, vertical integration, or Lilly's internal
reorientation toward pharmaceutical innovation, the global pharmaceutical
industry is searching for ways to meet these challenges. Professor Lasagna is
correct to emphasize the difficulty of fully meeting these challenges, but it is
my experience at Lilly that much has already been done to bring the industry
into a new era at the governmental, company, academic, and consumer levels.
While old ways are being cast aside, new opportunities are being created in the
laboratory, the physician's office, the board room, and the government's
regulatory agencies. However, it must be understood that it is only through a
partnership among industry, academia, government, and consumers that the
pharmaceutical industry will be able to provide safe, effective, and affordable
globally-available responses to the threats to human health in the global era.
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